Mounjaro
(tirzepatide)
Once-weekly injection. The only dual-action GIP and GLP-1 treatment, with the strongest results seen in clinical trials — average weight loss of 20% or more at higher doses over 72 weeks. MHRA-licensed.
LICENSED PHARMACY & UK-LICENSED DOCTORS · FREE DISCREET DELIVERY
SEMAGLUTIDE · NOVO NORDISK · DAILY ORAL GLP-1
NEWWEGOVYTABLETS
1DAILY DOSE
0INJECTIONS
64WEEK — OASIS 4
MHRALICENSED
Free discreet delivery
*Individual results vary and all trial results included lifestyle support.
The weight loss revolution, without the needle. Wegovy tablets are the UK's first licensed daily GLP-1 weight loss pill — approved by the MHRA in June 2026 — delivering the proven effects of semaglutide in a once-daily tablet, with weight loss in trials comparable to the weekly Wegovy injection.
ABOUT THE MEDICATION
WHAT ARE WEGOVY TABLETS?
Wegovy tablets contain semaglutide — the same active ingredient as the Wegovy weekly injection — as a once-daily oral tablet. On 11 June 2026 the MHRA approved them for weight management, making the UK the first country in Europe to license a daily GLP-1 weight loss pill, with private availability from July 2026.
They're licensed for adults with a BMI of 30+, or 27+ with at least one weight-related condition (type 2 diabetes, hypertension, high cholesterol, sleep apnoea, cardiovascular disease), alongside a reduced-calorie diet and increased physical activity.
KEY BENEFITS
ONCE DAILY, NO INJECTIONS
The same active ingredient as the Wegovy weekly injection, as a once-daily oral tablet.
INJECTION-COMPARABLE RESULTS
Over 64 weeks, average weight loss was around 13–14% — results comparable to the 2.4 mg weekly injection.
MHRA-LICENSED
MHRA-approved on 11 June 2026, the first daily GLP-1 weight loss pill licensed in the UK.
SNAC ABSORPTION TECHNOLOGY
An absorption enhancer that creates a locally protective environment at the stomach lining so a portion of the dose crosses intact.
How it works
01
FREE ONLINE ASSESSMENT
Complete a free online weight loss assessment.
02
PRESCRIBER REVIEW
If Wegovy Tablets are clinically appropriate for you, our GPhC-registered pharmacy will dispense your treatment.
03
FREE TRACKED DELIVERY
Free, discreet, tracked delivery — with reviews built in.
01
FREE ONLINE ASSESSMENT
Complete a free online weight loss assessment.
02
PRESCRIBER REVIEW
If Wegovy Tablets are clinically appropriate for you, our GPhC-registered pharmacy will dispense your treatment.
03
FREE TRACKED DELIVERY
Free, discreet, tracked delivery — with reviews built in.
CHECK IF YOU QUALIFY FOR GLP-1 WEIGHT LOSS TREATMENT
GLP-1 weight loss treatments are licensed for adults who meet one of the following criteria, alongside a reduced-calorie diet and increased physical activity:
- A BMI of 30 kg/m² or above (obesity), or
- A BMI of 27 kg/m² or above (overweight) with at least one weight-related condition, such as type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnoea or cardiovascular disease.
BMI thresholds may be adjusted for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, who are at higher cardiometabolic risk at lower BMIs.
Meeting the BMI criteria alone doesn't guarantee suitability — our prescribers review your full medical history. GLP-1 treatments are not suitable during pregnancy or breastfeeding, or for people with a personal or family history of medullary thyroid carcinoma or MEN 2, among other contraindications your prescriber will assess.
Weight loss treatment eligibility
- 1Basic Info
- 2Ethnic group
- 3Health conditions
- 4Results
Basic Info
What is your height?
What is your weight?
WEGOVY® TABLETS
- SNAC absorption technology
- 25 mg daily maintenance dose
- Once daily — no injections
- MHRA approved June 2026
SNAC absorption technology
25 mg daily maintenance dose
Once daily — no injections
MHRA approved June 2026
TRIAL WEIGHT LOSS RESULTS
~13–14%
average weight loss over 64 weeks OASIS 4 trial (25 mg oral semaglutide)
- WEGOVY TABLETS~13-14%
- WEGOVY INJECTION~15%
- FOUNDAYO~11-12%
Cross-trial comparisons are indicative only; individual results vary and all trial results included lifestyle support.
What Are They?
UK's First Daily GLP-1 Pill
How a Peptide Survives Your Stomach: SNAC Technology
Semaglutide is a peptide, and stomachs destroy peptides — that's why GLP-1 medicines have historically been injections. Wegovy tablets solve this with SNAC, an absorption enhancer that creates a locally protective environment at the stomach lining so a portion of the dose crosses intact. It works — but only under precise conditions, which is why the taking-it-correctly routine below isn't optional advice; it's the mechanism.
How It Works
Same Molecule, Different Route
Semaglutide mimics GLP-1, the fullness hormone released after eating: appetite drops, the mental 'food noise' quietens, the stomach empties more slowly so meals satisfy for hours, and blood sugar steadies. The tablet delivers the identical mechanism to the injection — the only difference is the route in.
Reduces food noise
Appetite drops and the mental 'food noise' quietens.
Slows gastric emptying
The stomach empties more slowly so meals satisfy for hours, and blood sugar steadies.
Shorter tail than the injection
Daily dosing also means steady drug levels with a shorter tail: some patients prefer knowing that if side effects bite or plans change, the medicine clears faster than a weekly depot injection.
Not the Same as Rybelsus
Rybelsus is oral semaglutide licensed for type 2 diabetes at up to 14 mg daily. Wegovy tablets carry a separate licence for weight management at up to 25 mg daily. Same molecule, different licences, doses and indications — not interchangeable without prescriber guidance.
BrandLicenceMax Dose
RybelsusType 2 Diabetes14mg
Wegovy TabsWeight Management25mg
This Determines Your Results
HOW TO TAKE WEGOVY® TABLETS CORRECTLY
01
First thing, empty stomach
Take your tablet when you wake, before anything else — food, coffee, other tablets, everything.
02
Small sip of plain water only
No more than about 120 ml (half a glass). More water dilutes the protective SNAC environment and cuts absorption. Plain water only — not juice, tea or sparkling.
03
Swallow whole
Never split, crush or chew — the tablet's integrity is part of the delivery system.
04
Wait at least 30 minutes
No food, no other drinks, no other medicines for a minimum of 30 minutes. Longer is fine; shorter costs you dose.
05
Then live normally
After the wait, eat breakfast and take other medicines as usual.
Common Mistakes That Quietly Sabotage Results
Morning Coffee Too Soon
Morning coffee 'just this once' before the wait is up — caffeine habits are the number one adherence killer; keep the kettle for minute 31.
Other Morning Tablets
Taking it with other morning tablets — levothyroxine, PPIs and supplements all belong after the 30 minutes (levothyroxine users: see interactions below).
Too Much Water
A full glass of water 'to be safe' — counterintuitively, more water means less absorption.
Unpredictable Mornings
Unpredictable wake times — the tablet suits routines; if your mornings are chaos, be honest with yourself and consider the weekly injection instead.
Side Effects
FULL PICTURE &
HOW TO MANAGE THEM
FREQUENCY
SIDE EFFECTS
WHAT TO DO
VERY COMMON >1 IN 10
Nausea, diarrhoea, constipation, vomiting
Cluster around dose steps and settle; small bland meals, hydration, avoid rich food
COMMON — UP TO 1 IN 10
Reflux, bloating, burping, headache, fatigue, dizziness, hair shedding
Usually mild and transient; shedding relates to rapid loss and regrows
UNCOMMON
Gallstones, gallbladder inflammation, raised heart rate, hypoglycaemia (with diabetes medicines)
Report right-sided upper abdominal pain, fever or jaundice promptly
RARE BUT SERIOUS
Pancreatitis, severe allergic reaction, dehydration from prolonged vomiting
Severe persistent abdominal pain or facial/throat swelling: urgent medical help
The profile mirrors the injection — same molecule, same class effects. Tell any clinician before planned surgery or sedation that you take semaglutide (slowed stomach emptying is relevant to anaesthesia), and report suspected side effects via the MHRA Yellow Card scheme.
The Evidence
Clinical Evidence: What the Trials Show
OASIS 4 — The Licensing Trial
~13–14%
average weight loss vs ~2% placebo over 64 weeks with a substantial proportion losing 15%+
The MHRA approval rests on OASIS 4, a phase 3 trial of oral semaglutide 25 mg in adults with obesity or overweight plus a comorbidity. Over 64 weeks, average weight loss was around 13–14% versus roughly 2% with placebo, with a substantial proportion of participants losing 15% or more — results comparable to the 2.4 mg weekly injection, and the basis for the MHRA permitting direct switching between the two.
The Wider OASIS Programme
~15%
at 50 mg dose (OASIS 1)
Earlier OASIS trials tested oral semaglutide up to 50 mg, with OASIS 1 showing ~15% average loss at that dose — evidence that the oral route can fully match injections. The licensed UK dose is 25 mg, chosen for its balance of efficacy and tolerability.
Cross-trial comparisons are indicative only; individual results vary and all trial results included lifestyle support.
Dosing
Schedule
Wegovy tablets are titrated from a 1.5 mg starting dose to the 25 mg daily maintenance dose over four months.
DURATION
DAILY DOSE
NOTES
Month 1
1.5mg
Starting dose
Month 2
4 mg
Step 2
Month 3
9 mg
Step 3
Ongoing
25 mg
Maintenance
MISSED DOSES
Skip it and take your next tablet at the usual time tomorrow — never take two in one day, and never take one later in the day after eating (it won't absorb properly anyway).
Switching from the injection
The MHRA permits patients established on the 2.4 mg weekly injection to move directly to the 25 mg tablet without re-titrating. Take the first tablet up to 7 days after the final injection. Switching tablet-to-injection is equally manageable — plan either move with your prescriber.
Progress Over Time
What to Expect:
Your Timeline
Month 1
1.5 mg
Tolerance-building dose; appetite changes usually begin within one to two weeks, scale movement modest.
Months 2–3
4 mg → 9 mg
Steady visible loss; brief side-effect flurries around each step-up are normal and settle.
Month 4+
25 mg
Full dose reached — the steepest part of the curve for most patients. Protein and strength training matter most now.
Months 6–15
25 mg
Gradual continued loss toward the trial average, then plateau — the cue for a maintenance conversation, not a sign of failure.
FULL RANGE
HOW WEGOVY TABLETS
COMPARE
RELATED TREATMENTS.
Real medication. Real doctors. No inflated prices. Just results.
Wegovy Injection
(semaglutide)
Once-weekly injection with an average 15% weight loss over 68 weeks in the STEP 1 trial, plus proven cardiovascular benefits in people with heart disease. One of the most widely prescribed weight loss treatments worldwide. MHRA-licensed.
New — MHRA-licensed
Foundayo
(orforglipron)
Eli Lilly's once-daily GLP-1 tablet, approved in the US in April 2026 and now licensed by the MHRA. It can be taken at any time of day, with or without food.
Brand discontinued — generic available
Liraglutide
(Saxenda)
£— / month
Once-daily injection. Branded Saxenda has been discontinued by Novo Nordisk, but generic liraglutide (Nevolat) contains the same medicine at the same dose and remains available for patients established on liraglutide or those it suits clinically.
Price includes medication only, if prescribed. An active FromMars membership is required and billed separately. Membership does not include or guarantee a prescription; medication is not available without a membership.
Drug Interactions
Interactions With Other Medicines
Levothyroxine:
Oral semaglutide increases levothyroxine exposure — thyroid monitoring is advised, and the 30-minute separation is essential. Flag thyroid medication in your consultation.
All Other Oral Medicines
Take them after the 30-minute window — both to protect semaglutide absorption and theirs. Slowed stomach emptying can also modestly alter absorption of narrow-window drugs (e.g. warfarin); monitoring can be arranged.
Diabetes Medicines
Insulin or sulfonylurea doses often need reducing to avoid hypoglycaemia.
Alcohol
No direct interaction; the usual advice — it aggravates nausea and adds calories, and tolerance often drops.
WARNINGS
Who Should Not Take Wegovy Tablets
DO NOT TAKE IF YOU ARE PREGNANT OR BREASTFEEDING
stop at least two months before a planned pregnancy.
DO NOT TAKE IF YOU HAVE A HISTORY OF PANCREATITIS
severe GI disease including gastroparesis, or alongside any other GLP-1 medicine.
USE WITH CAUTION IF YOU HAVE GALLBLADDER DISEASE HISTORY
diabetic retinopathy, and severe renal or hepatic impairment.
A PRACTICAL EXCLUSION: CONDITIONS OR MEDICINES THAT MAKE THE FASTING ROUTINE UNWORKABLE
(e.g. medicines that must be taken immediately on waking that can't be moved) — discuss in consultation.
Lifestyle
Diet, Lifestyle & Practicalities
- 01
Protein-First Eating
Protein-first eating (~1.2–1.6 g/kg target weight) and twice-weekly resistance training protect muscle during rapid loss.
- 02
Hydrate From Minute 31
Hydrate from minute 31 onward — reduced appetite blunts thirst, and hydration eases the main side effects.
- 03
Storage & Travel
Storage is simple: room temperature below 30°C in the original blister — no fridge, no sharps, and travel is as easy as any other tablet (keep the morning routine on your home clock or adjust gradually across time zones).
If you routinely eat under ~1,200 kcal, tell your clinician; a daily multivitamin is a sensible safeguard during rapid loss.
Long-Term Plan
Stopping Treatment & Maintenance
As with all GLP-1 medicines, appetite returns when treatment stops and regain is common without a plan. Options include continued maintenance dosing, a clinician-guided taper with structured lifestyle support, or switching formats.
One tablet-specific note: because daily dosing clears faster than a weekly injection, effects fade sooner after stopping — another reason to plan rather than drift.
Houston,
we have answers.
Houston,
we have answers.
Sources
References
- OASIS 4: oral semaglutide 25 mg for weight management — phase 3 results (Novo Nordisk; peer-reviewed publication).
- Knop FK et al. Oral semaglutide 50 mg in adults with overweight or obesity (OASIS 1). Lancet 2023;402:705–719.
- MHRA press release and Summary of Product Characteristics: Wegovy tablets (semaglutide), June 2026.
- Wegovy tablets Patient Information Leaflet, current version.
Pricing
Cost & What's Included
Wegovy tablets are priced per monthly pack, varying by dose strength — [£X] at starting doses to [£X] at 25 mg (typically aligned with the equivalent injection maintenance pricing). Prices include the prescriber consultation, ongoing pharmacist support and free tracked delivery — with no cold-chain constraints, tablets also suit letterbox delivery.
- Prescriber consultation included
- Ongoing pharmacist support
- Free tracked delivery
- No cold-chain constraints — suits letterbox delivery
- No fridge, no sharps
1.5 mgStarting dose
4 mgStep 2
9 mgStep 3
25 mgMaintenance
READY TO START?
GET WEGOVY®
TABLETS TODAY
Complete a free online consultation to find out if Wegovy tablets are right for you. Prescribed by UK clinicians, dispensed by our GPhC-registered pharmacy, delivered free and discreetly.